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Abstract 
For decades, the monogenetic bleeding disorders hemophilia A and B (coagulation factor VIII and IX 
deficiency) have been treated with systemic protein replacement therapy. Now, diverse molecular medicines, 
ranging from antibody to gene to RNA therapy, are transforming treatment. Traditional replacement therapy 
requires twice to thrice weekly intravenous infusions of factor. While extended half-life products may reduce 
the frequency of injections, patients continue to face lifelong burden of the therapy, suboptimal protection from 
bleeding and joint damage, and potential development of neutralizing anti-drug antibodies (inhibitors) that 
require less efficacious bypassing agents and further reduce quality of life. Novel non-replacement and gene 
therapies aim to address these remaining issues. A recently approved factor VIII-mimetic antibody 
accomplishes hemostatic correction in patients both with and without inhibitors. Antibodies against Tissue 
Factor Pathway Inhibitor (TFPI) and antithrombin-specific siRNA target natural anticoagulant pathways to 
rebalance hemostasis. Adeno-associated viral (AAV) gene therapy provides lasting clotting factor replacement 
and can also be used to induce immune tolerance. Multiple gene editing techniques are under clinical or 
preclinical investigation. Here, we provide a comprehensive overview of these approaches, explain how they 





Therapy for hemophilia is being completely transformed by diverse, disruptive molecular therapies. 
Congenital hemophilia A and B are X-linked bleeding disorders caused by mutations of the F8 gene (one in 
5,000 male births) or F9 gene (one in 30,000 male births), which lead to deficiencies of coagulation factor VIII 
(FVIII) or IX (FIX), respectively.1–5 While deficiencies of other clotting factors exist, one of which (FXI 
deficiency)  has been called hemophilia C, they show different clinical pictures.1,6 Hemophilia is characterized 
by painful and often spontaneous hemorrhages into joints and soft tissues which are life-threatening if 
intracranial, gastrointestinal, or in the neck/throat.2 Hemarthrosis accounts for 70-80% of all bleeding episodes, 
and leads to hemophilic arthropathy.2,7–9 FVIII or FIX level (normal range is 50-150 IU/dL) typically correlates 
with bleeding severity: <1 IU/dL of normal is classified as severe hemophilia, 1-5 IU/dL as moderate, and 5-50 
IU/dL as mild.2 The treatment of choice for management of acute bleeding is a recombinant or plasma-derived 
concentrate of FVIII or FIX.2 Those with severe hemophilia (approximately 45% of patients)10 require 
prophylactic replacement therapy to maintain trough FVIII or FIX levels of at least 1 IU/dL or higher, which 
reduces spontaneous bleeds and joint damage.2,11,12 Prophylaxis requires life-long intravenous infusions 2-3 
times per week due to the short half-lives of the clotting factors (endogenous/ standard-acting FVIII and FIX 
half-lives are 8-12 and 18-24 hours, respectively).2,5 Despite remarkably improved outcomes, prophylaxis fails 
to completely prevent bleeds and joint damage.13,14 
Development of FVIII- or FIX-neutralizing alloinhibitory antibodies (inhibitors) is currently the most 
serious complication of treatment as it makes replacement therapy ineffective and occurs in approximately 
30% and 5% of patients with severe hemophilia A and B, respectively.15 Clinical management and burden of 
therapy are more challenging in inhibitor patients, especially in those with hemophilia B, up to 50% of whom 
develop severe allergic reactions, including anaphylaxis, following administration of FIX.16,17 Patients with high-
titer inhibitors (>5 Bethesda units (BU)/mL, where 1 BU/mL reduces clotting factor activity by 50%) require 
bypassing agents, such as recombinant activated factor VII (rFVIIa) or activated prothrombin complex 
concentrate (aPCC). These are less efficacious and require more frequent infusions than factor concentrates in 
non-inhibitor patients.2,18 Immune tolerance induction (ITI) therapy may be given to eradicate high-titer 
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inhibitors, which entails many months or years of intensive, up to twice daily factor treatment and is only 
effective in approximately 70% and 30% of hemophilia A and B patients, respectively.19–21  
Several extended half-life factor products (EHLs) have been launched in recent years, which permit 
maintaining higher trough levels or reducing the frequency of infusions.13 Modifications to increase factor half-
life include its conjugation to polyethylene glycol (PEG),22 fusion to the Fc portion of immunoglobulin G23 or to 
albumin,24 and development of single-chain FVIII,25,26 which extend half-lives 1.2 to 2-fold for FVIII and 4- to 6-
fold for FIX.22,23,27–29 Yet, in many settings treatment expenditures are significantly higher in patients that switch 
to EHLs, which often prohibits using them despite their ability to increase trough levels and thus optimize 
protection from bleeding.30–32   
The limitations of standard therapies for patients with hemophilia, all of which are based on the same 
paradigm of replacing the missing protein, necessitate the search for better treatment options. This need is 
even more urgent in the case of patients with inhibitors, whose outcomes plummet upon development of 
alloinhibitory neutralizing antibodies. Many novel molecular therapies are currently being developed that 
promise to transform hemophilia care and patients’ quality of life. Gene therapy aims to provide sustained 
factor levels with a single treatment (Fig. 1), while non-replacement therapies mimic procoagulant activity of 
the missing clotting factor or enhance coagulation by inhibiting physiological anticoagulants (Fig. 2). Here, we 
summarize available data on these approaches, discuss their advantages and potential limitations, and 
forecast their impact on the management of hemophilia.   
 
Emicizumab: FVIIIa in disguise of an antibody 
Emicizumab is a subcutaneous humanized bispecific IgG4 monoclonal antibody that mimics a key 
function of activated FVIII (FVIIIa): bridging FIXa and the FX zymogen to accelerate activation of the latter. To 
that end, the antibody recognizes FIX/IXa with one Fab arm and FX/Xa with the other (Fig. 3). Emicizumab is 
not recognized by FVIII-neutralizing alloinhibitory antibodies, so it remains effective in their presence and is 
now licensed for bleed prophylaxis in hemophilia A patients, both with and without FVIII inhibitors.33,34  
Despite being able to mimic FVIIIa, emicizumab differs from it in several important ways that have 
implications for its efficacy, safety and laboratory monitoring (Table 1). Unlike FVIII, which circulates inactive in 
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the absence of bleeding, emicizumab does not require activation (it is always “on”).35 As a result, activated 
plasma thromboplastin time (aPTT, a clotting-based assay routinely used to monitor response to standard 
therapies) overestimates coagulation in patients on emicizumab, because its constant “on” state skips the time 
normally needed to generate FVIIIa.36 Other clotting-based assays also suffer from this problem, such as 
underestimation of FVIII inhibitor titers during Bethesda assays, which are further complicated by emicizumab 
retaining its activity despite the presence of FVIII inhibitors.37 Additionally, in contrast to FVIIIa, which loses 
activity upon spontaneous dissociation of non-covalently bound A2 domain or cleavage by activated protein C, 
emicizumab is never inactivated.35 Emicizumab lacks phospholipid-binding sites, but its procoagulant activity 
still depends on negatively-charged phospholipids. This probably limits its activity to the sites of blood vessel 
injury, where exposure of phosphatidylserine on the outer side of plasma membrane recruits coagulation 
factors with Gla domains (including FIX and FIX).38,39 Emicizumab binds FIX/IXa and FX/Xa more weakly than 
FVIIIa binds FIXa and FX, which keeps emicizumab from sequestering FIX and FX zymogens and facilitates 
the release of FXa for its downstream reaction (thrombin generation).40 Despite emicizumab’s insusceptibility 
to activated protein C, inhibition of FVa therewith as well as inhibitory activities of tissue factor pathway 
inhibitor (TFPI) and antithrombin seem to regulate the procoagulant activity of emicizumab well enough.41,42  
In clinical trials, emicizumab was administered prophylactically once a week, every other week or every 
four weeks, and these three regimens have been used post-licensure.33,34,43–45 In HAVEN 1 and 3 studies, the 
drug reduced bleeding rates in persons with hemophilia A with and without FVIII inhibitors by 79 and 68% 
compared to pre-emicizumab prophylaxis with standard bypassing agents (aPCC and rFVIIa) and FVIII, 
respectively.46,47 Management of breakthrough bleeds on emicizumab still requires standard therapies. While 
administration of FVIII concentrates in patients on emicizumab seems to be safe, several individuals with 
inhibitors developed thromboses or thrombotic microangiopathy (TMA) after treatment with higher dose 
aPCC.33,34 FVIII probably outcompetes emicizumab for their common substrates (FIXa and FX) due to the 
lower affinity of the latter, thereby producing no synergistic effects. In contrast, aPCC contains several 
coagulation factors (FII, FVII, FIX, FX and activated FVII), two of which are the substrates of emicizumab, and 
one of which (FIX) drives the synergistic effect of aPCC and emicizumab on thrombin generation.48 This is 
because in normal hemostasis the generation of FVIIIa is the limiting step in formation of the FVIIIa/FIXa/FX 
complex, while in FVIII-deficient plasma containing emicizumab, which is active en bloc and thereby available 
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in excess immediately when bleeding occurs, the limiting step of the emicizumab/FIXa/FX complex formation is 
the generation of FIXa.37,39 The immunogenicity profile of emicizumab seems favorable and similar to other 
humanized therapeutic monoclonal antibodies (Table 1).49–51 
The dosing regimens of emicizumab aim at maintaining its plasma concentration close to 50 µg/mL, 
which provides hemostatic activity equivalent to ~15 IU/dL of FVIII, estimated by comparing emicizumab with 
FVIII in thrombin generation assays. This is a major departure from 1 IU/dL FVIII trough levels (traditionally 
aimed for with standard FVIII concentrate prophylaxis), which likely translates into further reduced bleeding 
rates.39,45,52  
 
Targeting physiological anticoagulants 
 Individuals with hemophilia who co-inherit prothrombotic mutations may show milder bleeding 
phenotypes. This observation prompted attempts to correct the bleeding phenotype in hemophilia by 
downregulating natural anticoagulants, thereby rebalancing hemostasis.53,54 Several approaches are currently 
under study in patients with hemophilia A and B, two of which are at the clinical stage: blocking tissue factor 
pathway inhibitor using monoclonal antibodies and knocking down antithrombin through RNA interference 
(RNAi). Potentially, anti-TFPI antibodies and fitusiran could be used to treat von Willebrand disease and some 
rare bleeding disorders (e.g. FVII deficiency) but available data are limited to in silico and in vitro studies.55–57 
 
Anti-TFPI antibodies 
Several TFPI-targeting molecules have been investigated over the years, four of which (concizumab, 
BAY 1093884, marstacimab and MG1113) are subcutaneous anti-TFPI antibodies that entered clinical trials 
including both hemophilia A and B patients with and without inhibitors. A Phase 2 BAY 1093884 trial has now 
been terminated due to serious adverse events. Tissue factor pathway inhibitor (TFPI) brakes the initiation 
phase of coagulation by inactivating FXa (with its Kunitz-type serine protease inhibitor domain 2 or K2) and the 
FVIIa-tissue factor (TF) complex (via the K1 domain). These two events proceed stepwise: the binding of FXa 
enables the inhibition of FVIIa-TF.58,59 Therefore, TFPI operates in a negative feedback loop that regulates the 
generation of FXa. Interestingly, partial TFPI deficiency is not a strong risk factor for thrombosis, but it may 
ameliorate the bleeding phenotype when co-inherited with hemophilia.53,54,60  
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The four antibodies that entered the clinic target K2 or both K1 and K2 domains of TFPI (Table 2). 
Since TFPI requires FXa to effectively modulate FVIIa, blocking the K2 domain unleashes both factors. This 
extends the initiation phase of coagulation, which thus generates more FXa (Fig. 4). In hemophilic plasma, this 
may compensate for the insufficient FXa (and so thrombin) generation caused by deficiencies of FVIII or FIX. 
In the ongoing phase 2 trials, once daily prophylaxis with concizumab reduced annualized bleeding rates 
(ABRs) in patients with hemophilia A or B with inhibitors compared to on-demand treatment with rFVIIa.61  
 Several issues common for all these anti-TFPI antibodies transpire from the available data. They all 
exhibit target-mediated drug disposition (TMDD, whereby pharmacokinetics are affected by the drug’s high 
binding affinity).62–65 The key implication is the necessity for more frequent infusions than could be otherwise 
expected from an antibody, given their long half-lives. Consequently, the ongoing phase 2/3 trials administer 
anti-TFPI antibodies as often as once daily.66 Also, TMDD and compartmentalization of various TFPI isoforms 
complicate the search for a safe therapeutic window. For example, the highest dose (0.8 mg/kg) of concizumab 
used in a phase 1 multiple-dose trial, which normalized thrombin generation, also caused elevation of D-dimer 
and prothrombin F1 + 2 (prothrombotic markers) levels above the normal range, although the relevance of these 
markers in individuals with hemophilia is unknown and no evidence of thromboses was seen.66–68  
Treatment of breakthrough bleeds will require standard therapies, because TFPI primarily acts on the 
initiation phase of coagulation, which is already shut down at the time of intervention in a typical acute bleeding 
scenario (Fig. 1). Potential synergistic effects of anti-TFPI antibodies with standard therapies await elucidation. 
Recent in vitro and in vivo studies on interactions between concizumab and rFVIIa yielded conflicting results. 
While concizumab and rFVIIa showed synergistic effect on thrombin generation in vitro, no such effect 
emerged in hemophilic rabbits or cynomolguses.69 The authors propose that rFVIIa at pharmacological doses 
activates FX independent from TF on the surface of activated platelets in the propagation phase of 
coagulation, while TFPI only acts in the initiation phase.70 However, upon activation, platelets release their 
intracellular pool of TFPI, part of which remains on the platelet surface and may be blocked by anti-TFPI 
antibodies (Fig. 4).71–73 Indeed, in hemophilic mice, platelet-derived TFPI seems to be a major regulator of 




Fitusiran (ALN-AT3) is a subcutaneous double-stranded small interfering (si)RNA that targets the 
transcript of the SERPINC1 gene, leading to its degradation by RNA-induced silencing complex (RISC) and 
thus preventing translation (Fig. 5).76 SERPINC1 encodes antithrombin (AT), a serine protease inhibitor 
(serpin) produced by hepatocytes, which irreversibly inactivates thrombin, FXa and, to a lesser extent, FIXa, 
FXIa, FXIIa, kallikrein and plasmin.77  
 Fitusiran targets a 23-nucleotide region of the SERPINC1 mRNA (NM_000488.2 positions 815–837).78 
The RNA backbone of fitusiran contains chemical modifications (including 2′-deoxy-2′-fluoro, and 2′-O-methyl 
substitutions in ribonucleotides and undisclosed replacements of phosphodiester linkages between them) that 
prevent its degradation by nucleases and recognition by Toll-like receptor (TLR)3 and TLR7, which are innate 
immune receptors sensing double-stranded RNAs.78–81 Also, the siRNA is conjugated to triantennary N-
acetylgalactosamine (GalNAc), which mediates its uptake by hepatocytes through asialoglycoprotein receptor 
(ASGPR), abundantly expressed in the liver.78,82 The antisense strands of siRNAs are stable within the RISC 
for weeks, so the same siRNA molecule may target multiple transcripts, which produces a durable knockdown, 
and so therapeutic effect (fitusiran is dosed once monthly in the ongoing trials). A few hundred siRNAs per cell 
are enough for efficient and sustained knockdown.82  
 Phase 3 trials of fitusiran are ongoing (Table 3). Data reported so far demonstrated dose-dependent 
increase in thrombin generation, inversely correlating with reduction of antithrombin. A reduction in the 
antithrombin level of more than 75% from baseline elevated thrombin generation to non-hemophilic levels.83 In 
a phase 2 trial, which included patients with hemophilia A and B with and without inhibitors, such drop in 
antithrombin levels reduced the overall median ABR to 1, with 48% patients remaining bleed-free throughout 
the study. Breakthrough bleeds were treated with clotting factor concentrates or bypassing agents. The most 
serious adverse event was a fatal cerebral venous sinus thrombosis, which prompted suspension of all trials. 
The fatal case occurred after repeated infusions of high FVIII concentrate doses over more than 24 hours, 
which was contraindicated for trial participants. Importantly, the patient’s FVIII levels were never above the 
normal range during the intensive FVIII treatment. The trials resumed in December 2017.84 During the period of 
dosing suspension, AT levels recovered and rose to more than 60% of baseline after 5 months while thrombin 
generation decreased and ABR increased to 6.85  
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Gene therapy  
AAV gene therapy for hemophilia B 
Adeno-associated virus (AAV) is a non-pathogenic single-stranded DNA parvovirus that is naturally 
replication deficient in the absence of helper virus co-infection.  Recombinant AAV (rAAV) vectors lack 
sequences encoding Rep, Cap, and AAP (for replication, capsid structure, and promoting capsid assembly, 
respectively) and generally elicit only mild and transient innate immune responses compared to other viral 
vectors.86–90 Also, AAV integration into the host genome occurs inefficiently in the absence of the rep gene,91–93 
reducing risks of genotoxicity. Efficient in vivo gene transfer, various viral capsids with strong tropism for the 
liver, and ability to confer long-term gene expression in hepatocytes has made AAV the vector of choice for 
most hemophilia gene therapy clinical trials.94–100 Currently, AAV vectors are produced using two vastly 
different manufacturing platforms: human embryonic kidney (HEK) 293 cells (Fig. 1A) or Sf9 insect cell-based 
baculovirus expression vector system (Fig. 1B). The vector in all current clinical trials is given intravenously, 
and the transgene is expressed from a liver-specific promoter (Fig. 1C). This approach has resulted in 
therapeutic expression for more than a decade in large animal studies, and similarly in long-term expression of 
~5% of normal FIX levels in patients enrolled in early trials. Hurdles for the approach include pre-existing 
neutralizing antibodies (NAbs) against some capsids that exclude some patients from receiving a specific 
vector product. Mild liver toxicity and CD8+ T cell responses to viral capsid during the first few months after 
vector administration have prompted the prophylactic or acute use of glucocorticoids upon a systemic rise in 
liver enzyme levels.  
 Results of early clinical trials prompted many refinements, such as codon-optimization for enhanced 
expression and elimination of potentially immune stimulatory CpG motifs from expression cassettes. 
Transgenes encoding wild-type FIX have been replaced by FIX variants with higher activity such as the Padua 
variant, which contains p.R338L single amino acid substitution and shows 8-times higher activity.99–103 A 2015 
phase 1/2 clinical trial (Spark/Pfizer; NCT02484092) infused 15 hemophilia B patients with low-dose AAV-
Spark100 vector expressing FIX-Padua (SPK-9001, PF-06838435, fidanacogene elaparvovec) (Table 4).96,104 
Patients typically reached levels of 30% of normal or greater at a reported dose of 5e11 vector 
genomes/kilogram (vg/kg) and therefore no longer required factor infusions. Only two patients received 
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glucocorticoids to stymie AAV capsid-specific cellular immune responses.96 Phase 3 study of SPK-9001 
(Pfizer; NCT03861273) has begun and will test 55 additional patients. Similar levels of FIX activity have now 
been obtained using an AAV5 vector expressing FIX-Padua; although reported doses were substantially higher 
(2e13 vg/kg), no sustained AAV5 capsid-specific T cell response was detected (Uniqure; NCT03489291).95 
This vector has now also entered phase 3 study (Uniqure; NCT03569891).  
 
AAV gene therapy for hemophilia A  
AAV vectors with genomes exceeding the ~5 kb capsid packaging limit are truncated and have 
substantially reduced efficiencies, which has made the ~7 kb length of FVIII coding sequence a significant 
challenge in pursuit of gene therapy for hemophilia A.105 A 2015 phase 1/2 trial (BioMarin; NCT02576795) 
tested first-in-human AAV-mediated FVIII gene transfer (BMN 270, valoctocogene roxaparvovec) in nine 
severe hemophilia A patients (Table 5).94 They used a B-domain deleted FVIII (BDD-FVIII) that leaves 14 
codons in the B-domain for proteolytic cleavage/activation of FVIII (“FVIII-SQ”), retaining the potency of wild-
type FVIII at only ~4.4 kb.106–108 To further reduce size, a small hybrid liver-specific promoter (HLP) was 
constructed by combining the core enhancer from apolipoprotein E hepatic control region and three human 
alpha-1 antitrypsin promoter regulatory domains (ApoE/hAAT).109 AAV5 capsid was chosen in part because 
NAbs to AAV5 are less prevalent in humans than to AAV2 or AAV8.110,111 Vector doses of 6e13 vg/kg and 4e13 
vg/kg normalized or near-normalized FVIII levels at week 52 to a median of 88.6 and 31.7 IU/dL (measured by 
aPTT), respectively.94,112 For both cohorts, annualized bleeding rates (ABRs) dropped and remained at a 
median of 0 bleeds/year (mean 0.7 bleeds/year) between year two and three after therapy, while FVIII usage 
decreased by >95%.94,112,113 Intriguingly, in both cohorts FVIII levels declined to a median of 45.7 IU/dL (6e13 
vg/kg) and 23.5 IU/dL (4e13 vg/kg) during the second year of follow-up and continued to decline, albeit at the 
slower rates of 5.72 and 1.56 IU/dL, respectively, suggesting that durability of transgene expression may 
inversely correlate with vector dose. This is in contrast to the earliest successful hemophilia B trials, 
participants of which continue to show steady FIX levels nine years after therapy. Also, hemophilia A dogs 
showed stable FVIII expression over a decade after gene therapy.114 These observations point to potential 
overarching principles underlying the FVIII decline in the BioMarin trials. FVIII is naturally synthesized in liver 
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sinusoidal endothelial cells (LSEC), not in hepatocytes.115 Also, AAVs may transduce a smaller percentage of 
hepatocytes in humans compared to nearly complete transduction observed for vectors that are most optimal 
in murine and NHP models.116 Perhaps uptake of the bulk of a large number of viral particles or ectopic over-
expression of FVIII, which is known to have a potential for inducing ER stress responses, causes cellular 
stress due to unfolded protein response or other mechanisms. Alternative explanations would be a partial loss 
of vector genomes or transgene expression over time.117 Also, the latest trial updates drew more attention to 
discrepancies between FVIII activity assays, with aPTT (the most widely used assay in monitoring standard 
therapies) showing ~1.6-fold higher FVIII activities in the trial participants than a chromogenic substrate assay 
(CSA).94,113 This aroused the expectation that all companies report CSA along with aPTT results. Animal 
studies suggest that CSAs are more reliable in measuring transgenic FVIII activity but conclusive evidence has 
yet to be produced.118–120 This issue is germane to an ongoing debate over using factor level as the primary 
efficacy endpoint.121 BioMarin also initiated two studies in 2018, including a phase 3 trial (NCT03392974) and a 
phase 1/2 trial (NCT03520712) evaluating patients with preexisting anti-AAV5 NAbs.  
Several additional hemophilia A trials have been initiated by other entities (Table 5). A 2016 trial 
(Spark; NCT03003533) administered a bioengineered AAV8 expressing BDD-FVIII to twelve patients with 
hemophilia A at 5e11-2e12 vg/kg. Low and mid doses of vector resulted in mean FVIIII levels of 13 IU/dL at 66 
weeks and 15 IU/dL at 46 weeks, respectively, and >97% reduction in ABRs and FVIII usage.122 A 2017 phase 
1/2 trial (University College London; NCT03001830) administered two doses of AAV2/8 expressing a codon-
optimized FVIII transgene under an HLP promoter, into three severe hemophilia A patients.109,123 Their unique 
BDD-FVIII transgene contains a 17-amino-acid peptide with six N-glycosylation sites (FVIII-V3), which 
improved FVIII expression 3-fold in mice compared to the FVIII-SQ.123 In 2017, Sangamo began a phase 1/2 
study (NCT03061201) infusing SB-525, an AAV2/6 expressing BDD-FVIII under a liver-specific promoter, into 
patients with severe hemophilia A. The two higher doses (1e13 and 3e13 vg/kg) increased FVIII levels to mild 
hemophilia and normal levels (when measured by aPTT), respectively, and found the same discrepancies 
between aPTT and CSA as in the BioMarin studies.124,125 
In preclinical studies, uniQure is developing an AAV5-mediated gene therapy using a FIX variant with 
three amino acid substitutions (p.V181I, p.K265A, p.I383V), which corrects the hemophilia A phenotype by 
 12 
allowing FIX to function independently of FVIII (FIX-FIAV), and potentially could be used in patients with FVIII 
inhibitors.126 FIX-FIAV has ~30% activity of FVIII and is well-tolerated in non-human primates (NHPs), with 
sustained expression beyond 14 weeks. In hemophilia A mice, clotting activity was ~5% normal by the fifth 
week after vector administration.  
In vivo gene editing therapies for hemophilia 
A 2018 phase 1 trial (Sangamo; NCT02695160) infused SB-FIX, a hemophilia B gene therapy 
consisting of three liver-tropic AAV2/6 vectors, each delivering one of the three components: a right or left zinc 
finger nuclease (ZFN) or normal F9 transgene. The ZFNs are designed to place the normal copy of the clotting 
factor gene within the albumin intron 1, under control of the endogenous albumin locus promoter (Fig. 6). 
Preclinical studies showed that co-delivering AAV8 containing a ZFN pair targeting murine albumin (intron 1) 
with AAV8 containing a splice acceptor signal, promoterless F9 transgene (exons 2-8), and poly(A) sequence 
flanked by arms homologous to intron 1, can increase FIX levels proportionally to vector dose.127–129 Even 
when only 0.5% of the murine transcripts were mutated, high levels of FIX were sustained for more than a 
year, with no change in plasma albumin.  
While ZFNs are the only in vivo gene editing system in hemophilia clinical trials currently, others such 
as clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) 
are being investigated in preclinical studies. The CRISPR/Cas9 system consists of a guide RNA (gRNA), which 
is a combination of two single-stranded RNAs, CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA), 
and a nuclease (Cas9) that form the Cas9-gRNA complex.130 The gRNA scans the genome to look for a 
complementary sequence known as the protospacer adjacent motif (PAM) and then Cas9 cleaves if the 
adjacent DNA sequence also matches the remaining gRNA. The double-strand break can be repaired by 
homologous recombination if a DNA donor template is present that has flanking arms homologous to the DNA 
at the Cas9 cleavage site (Fig. 7). A dual AAV approach codelivering the Staphylococcus aureus Cas9 and 
FIX-encoding transgenes has been used to correct hemophilia B in mice.131 In this approach, the F9 transgene 
was targeted to exon 2 of the endogenous F9 locus. Intellia Therapeutics are testing codelivery of lipid-
nanoparticle encapsulated CRISPR/Cas9 components and an AAV containing a F9 transgene cDNA donor 
template in NHPs.132 They have achieved therapeutic levels of FIX after targeting the DNA into intron 1 of the 
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albumin locus. Applied StemCell is also using the same strategy to correct hemophilia A in NHP and 
humanized-liver mouse models.133,134 
Both Cas9- and ZFN-based gene editing systems prompt additional safety considerations related to at 
least transient and potentially constitutive expression of prokaryotic nucleases along with the therapeutic 
transgene. Also, both systems pose an unclear risk of off-target DNA mutagenesis.135,136 
 
Immune tolerance induction by liver gene transfer 
 Studies in both canine and murine models of hemophilia show that liver-directed gene therapy can 
induce tolerance against FVIII or FIX, through regulatory T cell induction.137–140 Hepatic gene transfer with 
AAV2/8 expressing FIX was shown to reverse preexisting anti-FIX NAbs and desensitize anaphylaxis-prone 
hemophilia B mice.141 These findings are further supported by the lack of reported inhibitors in any of the liver-
directed AAV clinical trials in hemophilia patients.94–100  
 
Ex vivo gene therapies for hemophilia 
Many gene therapy studies employ lentiviral vectors, which integrate into host genomes. These have 
several advantages over AAV, including avoidance of gene dilution as the transgene is replicated with the host 
genome, lower prevalence of preexisting anti-vector NAbs, and increased packaging limits (~8-10 kb).105,142 Yet 
integration is a concern if it occurs near a transcription start site and transactivates a proto-oncogene.143–145 
However, lentiviruses preferentially integrate within transcription units, thus are less likely to be genotoxic,146 
and multiple clinical trials involving lentiviral-mediated gene therapy for other diseases have not observed 
insertional mutagenesis.147–149  
While in animal models lentiviruses can generate stable FIX expression when targeted to 
hepatocytes,150 lentiviral clinical trials have focused on ex vivo transduction.147,148,151,152 A phase I trial in 2019 
(Medical College of Wisconsin; NCT03818763) plans to use a lentiviral vector to deliver the FVIII gene, under a 
platelet-specific promoter, into autologous hematopoietic stem cells (HSCs) ex vivo, and then infuse these cells 
into hemophilia A patients.153–155 Platelets are a site for synthesis/storage of von Willebrand factor (VWF), 
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which forms a complex with FVIII and might help retain FVIII intracellularly until it is needed.155 In mice, this 
strategy was shown to protect FVIII from inactivation by inhibitors.156  
 
Future directions in hemophilia treatment 
After decades of stagnation, hemophilia care has become an extremely fertile environment spurring a 
myriad of new technologies, many of which have reached the clinic. Emicizumab, now licensed for bleed 
prophylaxis in hemophilia A with and without inhibitors, was the first to break the paradigm of frequent 
intravenous infusions and seesaw PK. This creates unique opportunities to improve outcomes, including in 
very young children, which has been unfeasible with standard therapies.157,158 Inhibitors of natural 
anticoagulants: fitusiran and anti-TFPI antibodies, are far along in clinical trials, and, if licensed, will greatly 
facilitate prophylaxis in hemophilia A and B in general, and patients with inhibitors in particular.159 Hemophilia B 
patients with inhibitors, who have been clinically the most underserved subpopulation, may benefit the most.  
Historically, gene therapy has been the holy grail of hemophilia care and its curative potential became 
tangible with several approaches producing normal levels of FVIII or FIX in hemophilia patients. The field has 
made great strides since its underwhelming beginnings and continues to evolve with still much room for 
improvement. AAV vectors have become the workhorse for both gene addition and correction, and future 
research will focus on perfecting capsid, transgene, and promoter designs in pursuit of better transduction 
efficiencies, immunological inertness and predictability of therapeutic effect. Compared to almost 100% 
transduction efficiencies in animal models, the estimated few percent of hepatocytes transduced in humans 
leaves a lot to be desired in terms of achieving high protein expression without risking protein overload cellular 
stress.116 Also, while all the ongoing clinical trials for hemophilia A and B target hepatocytes, FVIII is naturally 
expressed in liver sinusoidal endothelial cells (LSECs),160,161 which will drive attempts to retarget AAVs for 
hemophilia A to the liver endothelium. Cancer gene therapy has made remarkable progress in vector 
engineering to target otherwise non-permissive cells, which may inform such efforts in hemophilia.162  
Future treatment options may include prophylactic immune tolerance induction to prevent development 
of FVIII and FIX inhibitors. Oral tolerance induction using transplastomic lettuce expressing FVIII or FIX fused 
to a transmucosal carrier is at the forefront of research in this area.163 Such bioencapsulated factors can be 
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ingested, cross the intestinal epithelium and induce regulatory T cells within the gut-associated lymphoid tissue 
(GALT).164,165 Murine and canine studies show that this strategy can reduce or prevent inhibitor formation, 
making it a likely candidate for clinical trials.  
With this expanding tool chest, clinicians and patients are looking at a promising future but also 
entering an uncharted territory. Safety will need to remain a top priority with the legacy of medical disasters 
that plagued the hemophilia community in the past.166 Nevertheless, a new revolution in hemophilia treatment 
is now in full gear.   
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Table 1: Differences between FVIII and emicizumab. VH, heavy chain variable region; VL, light chain variable region; Ig, immunoglobulin; mAb, 
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Table 2: Anti-TFPI antibodies that entered clinical trials. ABRs, annualized bleeding rates; mAb, monoclonal antibody; SC, subcutaneous; Ig, 
immunoglobulin; scFv, single-chain variable fragment; TFPI, tissue factor pathway inhibitor; PK, pharmacokinetics; PD, pharmacodynamics; NAbs, 








Ongoing clinical trials Completed clinical trials 
Frequency, route 
and dose in active 
trials 







epitope within the 
K2 domain of TFPI 
93%66,67 
Phase 2 (NCT03196297): efficacy 
and safety of once daily 
prophylaxis in patients with severe 
hemophilia A without inhibitors 
 
Phase 2 (NCT03196284): efficacy 
of once daily prophylaxis in 
hemophilia A and B patients with 
inhibitors 
Phase 1 (NCT02490787): 
multiple dose, safety, PK 
and PD of concizumab in 
hemophilia A subjects 
once daily SC, 
loading dose 0.5 
mg/kg followed by 
0.15 mg/kg (with 
potential stepwise 








hemophilia A and B 
with inhibitors) 
ADAs detected in 




studies, none of which 





fully human (IgG1) 
mAb, selected from 







converted to IgG1; 
epitope within the 
K2 domain of TFPI 
100% (in 
cynomolgus)63 
Phase 2 (NCT03363321): safety, 
tolerability and efficacy of long-
term treatment in subjects with 
severe hemophilia A and B with or 
without inhibitors 
Phase 1 (NCT02531815): 
safety, tolerability, PK and 
PD of single ascending 
dose in healthy subjects 
only; 
 
Phase 2 (NCT02974855): 
safety, tolerability, PK and 
PD multiple doses in 
subjects with severe 
hemophilia A and B, with 
or without inhibitors 
once weekly SC, 3 
doses tested: 150 
mg (after the first 
loading dose of 300 
mg), 300 mg (no 
loading dose) and 
450 mg (no loading 
dose) 
- 
ADAs detected in 
15/32 (3 NAbs) 
participants of 
NCT02531815 study; 
all NAbs (3) detected 
42 days after 
administration, when 
the drug effects had 
already dissipated, so 




fully human (IgG2) 
mAb, selected from 
a phage display 




converted to IgG2; 
epitope 
encompasses K1 
and K2 domains of 
TFPI173 
52 or 61% 
depending on 
the assay (in 
cynomolgus)64 
none (Phase 2 NCT03597022 
study has just been terminated 
due to serious adverse events)  
Phase 1 (NCT02571569): 
safety, tolerability and PK 
of increasing single doses 
and multiple doses in 
subjects with severe 
hemophilia A or B, with or 
without inhibitors 
 
Phase 1 (NCT03481946): 
PK and PD in patients 
with severe hemophilia A 
and B, with or without 
inhibitors 






Phase 1 (NCT03855696): safety 
and tolerability of a single 
ascending dose in hemophilia A 
and B patients without inhibitors 
and healthy subjects 
N/A 
single dose SC and 
IV, 6 doses: 0.5 
mg/kg (SC), 1.7 
mg/kg (SC), 3.3 
mg/kg (SC and IV), 
6.6 mg/kg (IV) in 
healthy subjects; 3.3 
mg/kg (SC), 6.6 
mg/kg and 13.3 




Table 3: Fitusiran trials. ABRs, annualized bleeding rates; SC, subcutaneous; PK, pharmacokinetics; BPA, bypassing agent; ABR, annualized 
bleeding rate; HRQOL, health-related quality of life; CFC, clotting factor concentrate. 






Phase 1, single-ascending and multiple-ascending 
dose, safety, tolerability and PK in patients with 
moderate or severe hemophilia A and B 
completed NCT02035605 
once weekly 0.015–




Phase 1/2, long-term safety and tolerability in patients 
with moderate or severe hemophilia A and B with or 
without inhibitors 
ongoing NCT02554773 
once monthly SC, 
fixed dose 50 or 80 
mg 
78-88 1.7 (1) 
Phase 3 (ATLAS-INH): efficacy (ABR, HRQOL) of 
fitusiran relative to prior on-demand treatment with 
standard BPA in patients with hemophilia A and B with 
inhibitors 
ongoing NCT03417102 once monthly SC, 
fixed dose 80 mg 
- - 
Phase 3 (ATLAS-A/B): efficacy (ABR, HRQOL) of 
fitusiran relative to prior on-demand treatment with 
CFC in patients with hemophilia A and B without 
inhibitors 
ongoing NCT03417245 once monthly SC, 
fixed dose 80 mg 
- - 
Phase 3 (ATLAS-PPX), ABR and HRQOL relative to 
prior prophylaxis with CFC or standard BPA in patients 
with severe hemophilia A and B with or without 
inhibitors 
ongoing NCT03549871 
once monthly SC, 
fixed dose 80 mg - - 
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Table 4: Current and planned gene therapy clinical trials for hemophilia B: FIX, clotting factor IX; LTFU, long-term follow-up; n.d., not 
disclosed; AAV, adeno-associated virus; SGIMI, Shenzhen Geno-Immune Medial Institute; TTR, transthyretin; ApoE/hAAT, apolipoprotein E 
enhancer/human alpha 1-antitrypsin promoter; ZFN, zinc finger nuclease; SJCRH, St. Jude Children’s Research Hospital. 






Enrollment Status Identifier 
Freeline FLT180a Synthetic Liver-specific FIX-Padua 
6e11-
2e12 1 18 Recruiting NCT03369444 





Spark100 ApoE/hAAT FIX-Padua 
5e11 2 15 Active, not recruiting NCT02484092 
n.d. 3 55 Recruiting NCT03861273 
Sangamo 
SB-FIX: Integration of 
corrective FIX transgene 
into albumin locus by 
AAV6-delivered ZFN 




modified with lentivirus 
encoding FIX 







scAAV8 TTR FIX-Padua 
2e11-
3e12 1, 2 30 
Active, not 
recruiting NCT01687608 
SJCRH scAAV2/8-LP1-FIX scAAV2/8 LP1 FIX 
2e11-













AMT-061 Liver-specific FIX-Padua 2e13 
2 3 Recruiting NCT03489291 
3 56 Recruiting NCT03569891 
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Table 5: Current and planned gene therapy clinical trials for hemophilia A: BDD-FVIII, B-domain deleted clotting factor VIII; n.d., not disclosed; 
AAV, adeno-associated virus; HLP, hybrid liver-specific promoter; MCW, Medical College of Wisconsin; SGIMI, Shenzhen Geno-Immune Medial 
Institute; TTR, transthyretin; UCL, University College London; FIX, clotting factor IX; ApoE/hAAT, apolipoprotein E enhancer/human alpha 1-
antitrypsin promoter; ZFN, zinc finger nuclease. 






Enrollment Status Identifier 





AAV5 HLP BDD-FVIII 
6e12-
6e13 1, 2 15 
Active, not 
recruiting NCT02576795 
6e13 3 130 Recruiting NCT03370913 
4e13 3 40 Recruiting NCT03392974 
Valoctocogene 
roxaparvovec (BMN 
270) in patients with 
AAV5 antibodies 







PBSC, modified with 
lentivirus encoding 
BDD-FVIII 
- - - - 1 5 
Not yet 
recruiting NCT03818763 
Sangamo SB-525 AAV2/6 Liver-specific BDD-FVIII 
9e11-




modified with lentivirus 
encoding FVIII 




TAK-755 (formerly BAX 




Liver-specific BDD-FVIII 5e11-2e12 1, 2 30 Recruiting NCT03003533 
SPK-8016 in patients 
with FVIII inhibitors n.d. BDD-FVIII 
Dose-
finding 1, 2 30 Recruiting NCT03734588 
UCL AAV2/8-HLP-FVIII-V3 AAV2/8 HLP FVIII-V3 
6e11-




Figure 1: AAV gene therapy. A) Plasmid/HEK293 mammalian cell rAAV production: HEK293 cells are cotransfected with 1) AAV expression 
plasmid containing the clotting factor transgene and tissue-specific promoter, flanked by ITRs, 2) plasmid containing the rep and cap genes and 3) 
helper plasmid containing adenovirus genes. B) Baculovirus/Sf9 insect cell rAAV production: Sf9 cells are coinfected with 1) AAV expression 
baculovirus containing the clotting factor transgene and tissue-specific promoter, flanked by ITRs, and 2) baculovirus containing the rep and cap 
genes. C) Liver-directed AAV gene therapy: rAAV is harvested by freeze-thawing transfected/infected cells, purified, and then injected 
intravenously. The transgene expression is targeted to hepatocytes using a liver-specific promoter and capsid with strong liver tropism. rAAV binds 
to a serotype-specific host cell receptor and is internalized by a clathrin-coated dynamin-dependent pathway into the endosomal compartment.175–178 
The rAAV is quickly transported using microtubules to the perinuclear region and undergoes conformational changes that expose regions of its 
capsid to allow for escape from the endosome and nuclear localization signals for trafficking into the nucleus.178–180 Clotting factor is expressed after 
AAV uncoats its capsid and converts to circular double-stranded DNA episome by annealing of plus and minus strands delivered to the same cell or 
second-strand synthesis using host polymerase.181,182 rAAV, recombinant adeno-associated virus; ITR, inverted terminal repeat. 
 
Figure 2: Key events and physiologic inhibitors of secondary hemostasis targeted by non-replacement hemophilia therapies. Upon vessel 
wall injury, normally subendothelial tissue factor (TF) is exposed to blood and binds to activated FVII (FVIIa), thus enhancing its catalytic activity. 
TF-FVIIa complex generates small amounts of FIXa and FXa. FXa and early (partially activated) forms of FV (FVae) associate on negatively 
charged phospholipids (via calcium ions) exposed on damaged endothelial cells and activated platelets, where they form early prothrombinase 
complex, which generates minute amounts of thrombin (initiation phase) by cleavage of FII (prothrombin). In the amplification phase, thrombin 
activates multiple coagulation factors, including cell surface-bound FVIII, FV and FXI. FVIIIa enhances the catalytic activity of FIXa, which activates 
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FXa. FXa and thrombin-activated FV generated during amplification phase now propel a thrombin burst on the surface of activated platelets 
(propagation phase), leading to cleavage of FI (fibrinogen) and formation of the fibrin clot.58,183–185 
 
Figure 3: Structure and activity of FVIIIa and emicizumab. FVIIIa forms a complex with activated FIX (FIXa, a serine protease) and FX (the 
zymogen), so that FIXa can activate the latter. In this reaction, FVIIIa functions as a molecular scaffold for FIXa, whose protease activity towards FX 
is otherwise 105- to 106-fold lower and insufficient to drive the thrombin burst and, ultimately, optimal blood coagulation. Emicizumab is an 
asymmetric humanized bispecific anti-FIXa/anti-FX antibody with mouse and rat complementarity determining regions (CDRs) grafted on a human 
immunoglobulin (IgG)4 with a kappa light chain. While FVIIIa binds multiple sites on FIXa and FX, emicizumab recognizes single epitopes within 
epidermal growth factor-like domain 1 (EGF1) of FIXa and EGF2 of FX. Unlike FVIIIa, emicizumab does not bind negatively charged phospholipids 
(e.g. PS, phosphatidylserine) but their presence is necessary for its procoagulant activity, which suggests that bridging FIXa and FX in proper 
orientation requires that they sit on the cell surface.39,168  
 
Figure 4: Key isoforms of tissue factor pathway inhibitor (TFPI) and their activities. Two predominant isoforms, TFPIα and TFPIβ, emerge 
through alternative splicing, and so differ in structure and localization. TFPIα is the full-length isoform consisting of three Kunitz-type domains, one 
of which (K3) shows no inhibitory function, but it binds protein S (PS), which localizes the circulating TFPIα to cell membrane surfaces upon blood 
vessel injury. TFPIβ is a truncated form of TFPIα, missing part of the C-terminus including the K3 domain, but instead it contains a 
glycophosphatidylinositol (GPI) anchor, which moors it to the cell membrane. Both isoforms block FXa and TF-FVIIa complex with K2 and K1 
domains, respectively, but TFPIα displays one more mode of FXa inhibition, which is by blocking its association with early (partially activated) forms 
of FVa (FVae), and operates in different mise-en-scènes. Endothelial cells and megakaryocytes are the main sites of TFPI expression. 
Megakaryocytes express TFPIα only, while endothelial cells produce both TFPIα and TFPIβ, so the GPI-anchored pool of TFPI resides on the 
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endothelium. The plasma pool of TFPIα also comes from the endothelium, because the TFPIα synthesized by megakaryocytes is stored in platelets, 
which only release it upon activation. Although TFPIα is altogether the more abundant isoform, TFPIβ represents most of the TFPI that is readily 
available.58 Anti-TFPI antibodies currently evaluated in clinical trials block K2 or both K1 and K2 domains of TFPI. 
 
Figure 5: Antithrombin knock-down by fitusiran. Fitusiran is a double-stranded small-interfering (si)RNA with multiple chemical modifications, 
which protect it from degradation by nucleases and prevent innate immune sensing. The triantennary GalNAc moiety targets fitusiran to hepatocytes 
through asialoglycoprotein receptor (ASGPR, also known as Ashwell-Morell receptor) and clathrin-mediated endocytosis. Upon a drop in pH, the 
siRNA departs from ASGPR and exits the endosome. The cytosolic RNA-induced silencing complex (RISC) captures the molecule and ejects one 
strand, leaving the antisense strand to bind to antithrombin (AT) mRNA and induce its sequence-specific cleavage and degradation. This thwarts 
translation of the AT transcript, leading to a drop in blood AT levels.79,81,82 
 
Figure 6: Gene editing by AAV-delivered ZFN and donor DNA template. The ZFNs are designed to place the normal copy of the clotting factor 
gene within the albumin intron 1, under control of the endogenous albumin locus promoter. Three adeno-associated virus (AAV) vectors are 
delivered, each providing one of the three components: a right or left zinc finger nuclease (ZFN) or clotting factor complementary DNA (cDNA) 
donor template.127,128,186 1) The AAV-expressed ZFN fuses a DNA-cleavage domain (FokI endonuclease) to a zinc finger DNA-binding domain. 2) 
The ZFN binding domain targets a specific sequence and then the cleavage domain induces a double-strand break. 3) The double-strand break can 
be repaired by homologous recombination if a DNA donor template is present with flanking arms homologous to the DNA at the ZFN cleavage site. 
4) Flanking the clotting factor cDNA is a poly(A) sequence (pA) and a splice acceptor signal (SA), which splices the transcribed clotting factor RNA 
to the splice donor (SD) of albumin exon 1 RNA to produce a messenger RNA (mRNA) fusion transcript. 5) The mRNA fusion transcript is translated 
into secreted clotting factor protein. 
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Figure 7: Gene editing by lipid nanoparticle-delivered CRISPR/Cas9 and AAV-delivered donor DNA. The clustered regularly interspaced short 
palindromic repeats (CRISPR)/Cas9 system consists of gRNA, which is a combination of two single-stranded RNAs, CRISPR RNA (crRNA) and 
trans-activating crRNA (tracrRNA), and a nuclease (Cas9) that form the Cas9-gRNA complex.130 The CRISPR/Cas9 components can be delivered 
by lipid nanoparticle in RNA form.132 1) The guide RNA (gRNA) scans the genome for a complementary sequence known as the protospacer 
adjacent motif (PAM) site and cleavage by Cas9 occurs if the adjacent DNA sequence also matches the remaining gRNA.130 2) The double-strand 
break can be repaired by homologous recombination if a DNA donor template, delivered by adeno-associated virus (AAV), is present with flanking 
arms homologous to the DNA at the Cas9 cleavage site. 3) Flanking the clotting factor cDNA is a poly(A) sequence (pA) and a splice acceptor 
signal (SA), which splices the transcribed clotting factor RNA to the splice donor (SD) of albumin exon 1 RNA to produce a messenger RNA 







































A) Plasmid/HEK293 mammalian cell rAAV production
B) Baculovirus/Sf9 insect cell rAAV production























































Plasma membrane with PS exposed




























































































modified phosphodiester bonds (undisclosed) 
double-stranded RNA backbone
modifications of ribonucleotides such as 
2′-deoxy-2′-fluoro, and 2′-O-methyl subsitutions 















AAV-delivered Zinc Finger Nucleases




























































gRNA and Cas9 mRNA
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Cas9 
endonuclease
Cas9/gRNA 
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